Histone deacetylase 3 (HDAC3) inhibitors as anticancer agents: A review

Area of Science:

• Medicinal Chemistry
• Epigenetics
• Drug Discovery

Background:

• Histone deacetylase 3 (HDAC3) is a key epigenetic target with therapeutic potential for various diseases, including cancers, neurodegenerative disorders, and inflammatory conditions.
• Inhibiting HDAC3 offers a promising strategy for drug design and discovery, attracting significant research interest.
• Developing effective HDAC3 inhibitors remains a challenge, necessitating further investigation into their structural properties.

Purpose of the Study:

• To provide detailed structure-activity relationship (SAR) analysis of HDAC3 inhibitors.
• To deepen the understanding of structural information crucial for designing potent HDAC3 inhibitors.
• To identify key structural clues for the future development of improved therapeutic agents targeting HDAC3.

Main Methods:

• Detailed analysis of structure-activity relationships (SARs) of existing HDAC3 inhibitors.
• Compilation and review of current knowledge on HDAC3 inhibitor structural data.
• Comparative analysis of different HDAC3 inhibitor scaffolds and their biological activities.

Main Results:

• Identification of key structural features that correlate with HDAC3 inhibitory activity.
• Elucidation of SAR trends that can inform rational drug design.
• Highlighting specific molecular interactions critical for potent inhibition.

Conclusions:

• The detailed SAR analysis provides valuable insights for designing novel and more effective HDAC3 inhibitors.
• Understanding the structural basis of HDAC3 inhibition is crucial for advancing therapeutic strategies.
• Further research focusing on these SARs can accelerate the development of HDAC3-targeted drugs for various diseases.